MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2018 International Congress

    T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review

    J. Baird, J. Quinn (Portland, OR, USA)

    Objective: A systematic literature review was conducted to synthesize the current state of knowledge on the role of T lymphocytes in Parkinson’s disease (PD) pathology…
  • 2018 International Congress

    Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

    P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

    Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…
  • 2018 International Congress

    Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity

    G. Ho, T. Imberdis, S. Nuber, U. Dettmer, D. Selkoe (Boston, MA, USA)

    Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…
  • 2017 International Congress

    Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease

    J. Koprich, P. Howson, T. Johnston, M. Hill, P. Ravenscroft, J. Brotchie (Toronto, ON, Canada)

    Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…
  • 2017 International Congress

    Clinical and Imaging and phenoconversion in the PARS prodromal cohort

    K. Marek, A. Siderowf, S. Eberly, D. Oakes, M. Stern, D. Russell, J. Seibyl, D. Jennings (New Haven, CT, USA)

    Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…
  • 2017 International Congress

    Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
  • 2017 International Congress

    Higher genetic load is associated with an earlier disease onset but not with more rapid disease progression in Parkinson’s disease

    S. Lerche, I. Wurster, B. Roeben, E. Schaeffer, C. Schulte, S. Akbas, A.-K. Hauser, C. Deuschle, T. Gasser, D. Berg, K. Brockmann (Tuebingen, Germany)

    Objective: To evaluate the influence of genetic variants on phenotypic variability and disease progression in PD patients. Background: Parkinson’s disease (PD) patients show a large…
  • 2017 International Congress

    The Corticobasal Degeneration Functional Rating Scale (CBD-FS)

    A. Lang, G. Stebbins, A. Boxer (Toronto, Canada)

    Objective: To develop a patient/care giver-reported scale that is capable of assessing functional disability in CBD that can be easily and reliably used in clinical…
  • 2017 International Congress

    WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

    D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)

    Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…
  • 2017 International Congress

    Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study

    K. Dashtipour, Z. Mari, J. Jankovic, C. Adler, M. Schwartz, M. Brin (Loma Linda, CA, USA)

    Objective: To explore minimal clinically important change perceived by patients as beneficial by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) using data from the…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley